Stable non-disintegrating dosage forms and method of making same
The present invention is a stable, non-disintegrable dosage form which combines the benefits of a microencapsulated substrate with the convenience of direct compression. The present invention is also directed to methods for producing directly compressed microencapsulated dosage forms to provide modified release and dosage form stability. The dosage unit can have a high active load.
1 . A method of making a pharmacologically active dosage, comprising:
(a) spray coating a plurality of substrates, comprising particles including at least one pharmacologically active agent, with a neutral lipid-based coating in an amount to provide microencapsulates having an active agent concentration at least about 50%; and
(b) directly compressing said microencapsulates resulting from step (a) in an amount of at least about 50% by weight microencapsulate to form a shelf stable non-disintegrable pharmacologically active dosage unit, which releases said active agent by dissolution over the therapeutic range.
2 . A method according to claim 1 wherein said microencapsulates have at least about 60% active agent by weight.
3 . A method according to claim 2 wherein said active agent is present in an amount of at least about 70% by weight.
4 . A method according to claim 3 wherein said active agent is present in an amount of at least about 80% by weight.
5 . A method according to claim 4 wherein said active agent is present in an amount of at least about 90% by weight.
6 . A method according to claim 1 wherein the level of microencapsulates in the unit dosage is at least about 60% by weight.
7 . A method according to claim 6 wherein said level of microencapsulates is at least about 70% by weight.
8 . A method according to claim 7 wherein said level of microencapsulates is at least about 80% by weight.
9 . A method according to claim 8 wherein said level of microencapsulates is at least about 90% by weight.
10 . A method according to claim 1 wherein said substrates are selected from the group consisting of (i) a granulate comprising active agent and one or more pharmaceutically acceptable diluents; (ii) active agent coated onto the surface of inert beads; and (iii) pellets comprising active agent and one or more pharmaceutically acceptable diluents.
11 . A method according to claim 1 wherein said coating step is conducted by fluidized bed-coating.
12 . A method according to claim 1 wherein said neutral lipid-based coating comprises a neutral lipid as a primary ingredient selected from the group consisting of triglycerides, waxes, and combinations thereof, in the substantial absence of monoglycerides and diglycerides.
13 . A method according to claim 12 wherein said triglycerides are selected from the group consisting of hydrogenated vegetable oils, hydrogenated animal fats, and combinations thereof.
14 . A method according to claim 13 wherein said triglyceride is a hydrogenated vegetable oil selected from the group consisting of hydrogenated soybean oil, hydrogenated palm oil, hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated canola oil, and combinations thereof.
15 . A method according to claim 12 wherein said wax is selected from the group consisting of paraffin wax, carnauba wax, beeswax, candelilla wax, and combinations thereof.
16 . A method according to claim 1 further comprising incorporating a hydrophobic material in said neutral lipid-based coating.
17 . A method according to claim 16 wherein said hydrophobic material is ethylcellulose.
18 . A method according to claim 1 further comprising an active agent in said neutral lipid-based coating prior to coating said substrates.
19 . A method according to claim 1 wherein said active agent is selected from the group consisting of antihistamines; antibiotics; antituberculosis agents; cholinergic agents; antimuscarinics; sympathomimetics; sympatholytic agents; miscellaneous autonomic drugs; iron preparations; haemostatics; cardiac drugs; antihypertensive agents; vasodilators; non-steroidal anti-inflammatory agents; opiate agonists; anticonvulsants; tranquilizers; chemotherapeutic agents; lipid lowering agents; H 2 -antagonists; anti-coagulant and anti-platelet agents; bronchodilators; stimulants; barbiturates; sedatives; expectorants; antiemetics; gastro-intestinal drugs; antithyroid agents; genitourinary smooth muscle relaxants; vitamins; minerals; amino acids; herbal agents; botanical agents; enzymes; unclassified agents; diabetes agents; steroids; glucocorticoids; antivirals; antifungals; antiparasitic agents; antidiabetic agents; and any combinations or mixtures of the foregoing.
20 . A method according to claim 19 wherein said active agent is selected from the group consisting of acetaminophen, caffeine, guaifenesin, an opioid analgesic, ranitidine, vitamin C, potassium chloride, niacin, anti-flush agents, lipid-lowering statins, and combinations thereof.
21 . A method according to claim 20 wherein said active agent comprises guaifenesin.
22 . A method according to claim 21 wherein said guaifenesin is present in an amount of at least about 55% by weight of said dosage unit.
23 . A method according to claim 22 wherein said guaifenesin is present in an amount of at least about 65% by weight of said dosage unit.
24 . A method according to claim 23 wherein said guaifenesin is present in an amount of at least about 75% by weight of said dosage unit.
25 . A method according to claim 19 wherein said active agent comprises niacin.
26 . A method according to claim 25 wherein said niacin comprises at least about 50% by weight of said dosage unit.
27 . A method according to claim 25 wherein said niacin comprises at least about 60% by weight of said dosage unit.
28 . A method according to claim 25 wherein said niacin comprises at least about 70% by weight of said dosage unit.
29 . A method according to claim 25 wherein said niacin comprises at least about 80% by weight of said dosage unit.
30 . A method according to claim 19 wherein said active agent comprises niacin and at least one other lipid-lowering statin.
31 . A method according to claim 19 wherein said active agent comprises niacin and at least one anti-flush agent.
32 . A method according to claim 19 wherein said active agent comprises niacin and fenofibrate.
33 . A method according to claim 20 wherein said active agent comprises an opioid analgesic.
34 . A method according to claim 33 wherein said opioid analgesic is selected from the group consisting of codeine, hydromorphone, hydrocodone, oxycodone, morphine, meperidine and combinations thereof.
35 . A method according to claim 20 wherein said active agent is acetaminophen.
36 . A method according to claim 35 wherein said acetaminophen comprises at least about 50% by weight of said dosage unit.
37 . A method according to claim 35 wherein said acetaminophen comprises at least about 60% by weight of said dosage unit.
38 . A method according to claim 35 wherein said acetaminophen comprises at least about 70% by weight of said dosage unit.
39 . A method according to claim 35 wherein said acetaminophen comprises at least about 80% by weight of said dosage unit.
40 . A method according to claim 1 which further comprises adding at least one excipient ingredient prior to directly compressing.
41 . A method according to claim 40 wherein said at least one excipient ingredient is included in the dosage form in an amount not to exceed 50% by weight of said dosage unit.
42 . A method according to claim 41 wherein said excipient is not greater than about 40% by weight of said dosage unit.
43 . A method according to claim 42 wherein said excipient is not greater than about 30% by weight of said dosage unit.
44 . A method according to claim 43 wherein said excipient is not greater than about 20% by weight of said dosage unit.
45 . A method according to claim 44 wherein said excipient is not greater than about 10% by weight of said dosage unit.
46 . A method according to claim 45 wherein said excipient is not greater than about 5% by weight of said dosage unit.
47 . A method according to claim 40 wherein said excipient is selected from the group consisting of flavoring agents, acidifiers, sweeteners, taste-maskers, lubricants and combinations thereof.
48 . A method according to claim 40 wherein said excipient comprises an ingredient selected from the group consisting of sucrose, dextrose, lactose, microcrystalline cellulose, xylitol, fructose, sorbitol, maltodextrin, polyethylene glycol (PEG), silicified microcrystalline cellulose and combinations thereof.
49 . A method according to claim 1 wherein said active dosage unit active agent dissolves from the active dosage form in the absence of disintegration during dissolution of active within the therapeutic range.
50 . A method according to claim 49 wherein said active agent is guaifenesin and said dosage unit is designed to release from about 10% to about 35% of said guaifenesin after one (1) hour and from about 50% to about 90% after eight (8) hours in vitro.
51 . A method according to claim 49 wherein said active agent is niacin in a one a day dosage unit wherein said unit is designed to release from about 5% to about 30% of said niacin after one (1) hour and from about 35% to about 70% after eight (8) hours in vitro.
52 . A method according to claim 49 wherein said active agent is niacin in a two a day dosage unit wherein said unit is designed to release from about 5% to about 40% of said niacin after one (1) hour and from about 25% to about 75% after four (4) hours in vitro.
53 . A method according to claim 1 wherein said dosage unit has an active agent “early and sustained” modified release.
54 . A method according to claim 1 wherein said dosage unit has an active agent release which is one of delayed, controlled, extended, site specific, slow, pulsatile, modified, and combinations thereof.
55 . A pharmacologically active dosage unit comprising:
a compressed non-disintegrable tablet comprising a plurality of substrates microencapsulated in a neutral lipid-based coating, said substrates comprising at least one pharmacologically active ingredient in an amount to provide a concentration of active agent of at least about 50% in said microencapsulate, and said microencapsulate included in said dosage unit in an amount of at least 50% by weight of said dosage unit such that said active ingredient exhibits modified release by dissolution throughout the therapeutic range prescribed for treating a patient in need of said active ingredient.
56 . A dosage unit according to claim 55 wherein said concentration of said active agent in said microencapsulate is at least about 60% by weight.
57 . A dosage unit according to claim 56 wherein said concentration of said active agent is at least about 70% by weight.
58 . A dosage unit according to claim 57 wherein said concentration of said active agent is at least about 80% by weight.
59 . A dosage unit according to claim 58 wherein said concentration of said active agent is at least about 90% by weight.
60 . A dosage unit according to claim 55 wherein the level of microencapsulate in said dosage unit is at least about 60% by weight.
61 . A dosage unit according to claim 60 wherein said level of microencapsulate is at least about 70% by weight.
62 . A dosage unit according to claim 61 wherein said level of microencapsulate is at least about 80% by weight.
63 . A dosage unit according to claim 62 wherein said level of microencapsulate is at least about 90% by weight.
64 . A dosage unit according to claim 55 wherein said substrates are selected from the group consisting of (i) a granulate comprising active agent and one or more pharmaceutically acceptable diluents; (ii) active agent coated onto the surface of inert beads; and (iii) pellets comprising active agent and one or more pharmaceutically acceptable diluents.
65 . A dosage unit according to claim 55 wherein said neutral lipid-based coating comprises a neutral lipid as a primary ingredient selected from the group consisting of triglycerides, waxes, and combinations thereof, in the substantial absence of monoglycerides and diglycerides.
66 . A dosage unit according to claim 55 wherein said triglyceride is selected from the group consisting of hydrogenated vegetable oil, hydrogenated animal fat, and combinations or mixtures thereof.
67 . A dosage unit according to claim 66 wherein said triglyceride is a hydrogenated vegetable oil selected from the group consisting of hydrogenated soybean oil, hydrogenated palm oil, hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated canola oil, and combinations thereof.
68 . A dosage unit according to claim 65 wherein said wax is selected from the group consisting of paraffin wax, carnauba wax, beeswax, candelilla wax, and combinations thereof.
69 . A dosage unit according to claim 55 wherein said neutral lipid-based coating further comprises a hydrophobic material.
70 . A dosage unit according to claim 69 wherein said hydrophobic material is ethylcellulose.
71 . A dosage unit according to claim 55 wherein said active agent is selected from the group consisting of antihistamines; antibiotics; antituberculosis agents; cholinergic agents; antimuscarinics; sympathomimetics; sympatholytic agents; miscellaneous autonomic drugs; iron preparations; haemostatics; cardiac drugs; antihypertensive agents; vasodilators; non-steroidal anti-inflammatory agents; opiate agonists; anticonvulsants; tranquilizers; chemotherapeutic agents; lipid lowering agents; H 2 -antagonists; anti-coagulant and anti-platelet agents; bronchodilators; stimulants; barbiturates; sedatives; expectorants; antiemetics; gastro-intestinal drugs; antithyroid agents; genitourinary smooth muscle relaxants; vitamins; minerals; amino acids; herbal agents; botanical agents; enzymes; unclassified agents; diabetes agents; steroids; glucocorticoids; antivirals; antifungals; antiparasitic agents; antidiabetic agents; and any combinations or mixtures of the foregoing.
72 . A dosage unit according to claim 71 wherein said active agent is selected from the group consisting of acetaminophen, caffeine, guaifenesin, an opioid analgesic, ranitidine, vitamin C, potassium chloride, lipid-lowering statins, niacin, anti-flush agents, and combinations thereof.
73 . A dosage unit according to claim 72 wherein the active agent is acetaminophen.
74 . A dosage unit according to claim 73 wherein said acetaminophen comprises at least about 50% by weight of said dosage unit.
75 . A dosage unit according to claim 73 wherein said acetaminophen comprises at least about 60% by weight of said dosage unit.
76 . A dosage unit according to claim 73 wherein said acetaminophen comprises at least about 70% by weight of said dosage unit.
77 . A dosage unit according to claim 73 wherein said acetaminophen comprises at least about 80% by weight of said dosage unit.
78 . A dosage unit according to claim 55 which further comprises a second active agent.
79 . A dosage unit according to claim 78 wherein said additional active agent is an opioid analgesic.
80 . A dosage unit according to claim 79 wherein said opioid analgesic is selected from the group consisting of codeine, hydromorphone, hydrocodone, oxycodone, morphine, meperidine and any combination of the foregoing.
81 . A dosage unit according to claim 55 which further comprises at least one excipient mixed with the microencapsulated substrates.
82 . A dosage unit according to claim 81 wherein said at least one excipient ingredient is included in the dosage form in an amount not to exceed 50% by weight of said dosage unit.
83 . A dosage unit according to claim 82 wherein said excipient is not greater than about 40% by weight of said dosage unit.
84 . A dosage unit according to claim 83 wherein said excipient is not greater than about 30% by weight of said dosage unit.
85 . A dosage unit according to claim 84 wherein said excipient is not greater than about 20% by weight of said dosage unit.
86 . A dosage unit according to claim 85 wherein said excipient is not greater than about 10% by weight of said dosage unit.
87 . A dosage unit according to claim 86 wherein said excipient is not greater than about 5% by weight of said dosage unit.
88 . A dosage unit according to claim 81 wherein said excipient is selected from the group consisting of flavoring agents, acidifiers, sweeteners, taste-maskers, lubricants and any combinations or mixtures of the foregoing.
89 . A dosage unit according to claim 81 wherein said excipient is selected from the group consisting of sucrose, dextrose, lactose, microcrystalline cellulose, xylitol, fructose, sorbitol, maltodextrin, polyethylene glycol (PEG), silicified microcrystalline cellulose, and combinations thereof.
90 . A dosage unit according to claim 71 wherein said active agent comprises guaifenesin.
91 . A dosage unit according to claim 90 wherein said guaifenesin is present in an amount of at least about 55% by weight of said dosage unit.
92 . A dosage unit according to claim 91 wherein said guaifenesin is present in an amount of at least about 65% by weight of said dosage unit.
93 . A dosage unit according to claim 92 wherein said guaifenesin is present in an amount of at least about 75% by weight of said dosage unit.
94 . A dosage unit according to claim 71 where said active agent comprises niacin.
95 . A dosage unit according to claim 94 wherein said niacin comprises at least about 50% by weight of said dosage unit.
96 . A dosage unit according to claim 94 wherein said niacin comprises at least about 60% by weight of said dosage unit.
97 . A dosage unit according to claim 94 wherein said niacin comprises at least about 70% by weight of said dosage unit.
98 . A dosage unit according to claim 94 wherein said niacin comprises at least about 80% by weight of said dosage unit.
99 . A dosage unit according to claim 71 wherein said active agent comprises niacin and at least one other lipid-lowering statin.
100 . A dosage unit according to claim 71 wherein said active agent comprises niacin and at least one anti-flush agent.
101 . A dosage unit according to claim 71 wherein said active ingredient comprises niacin and fenofibrate.
102 . A dosage unit according to claim 55 wherein said active dosage unit active agent dissolves in the absence of disintegration during dissolution of active within the therapeutic range.
103 . A dosage unit according to claim 102 wherein said active is guaifenesin and said dosage unit is designed to release from about 10% to about 35% of said guaifenesin after one (1) hour and from about 50% to about 90% after eight (8) hours in vitro.
104 . A dosage unit according to claim 102 wherein said active is niacin in a one a day dosage unit wherein said unit is designed to release from about 5% to about 30% of said niacin after one (1) hour and from about 35% to about 70% after eight (8) hours in vitro.
105 . A dosage unit according to claim 102 wherein said active is niacin in a two a day dosage unit wherein said unit is designed to release from about 5% to about 40% of said niacin after one (1) hour and from about 25% to about 75% after four (4) hours in vitro.
106 . A dosage unit according to claim 55 wherein said dosage unit has an active agent “early and sustained” modified release.
107 . A dosage unit according to claim 55 wherein said dosage unit has an active agent release which is one of delayed, controlled, extended, site specific, slow, pulsatile, modified, and combinations thereof.
108 . A pharmacologically active dosage unit comprising:
a compressed non-disintegrable tablet comprising a plurality of substrates microencapsulated in a neutral lipid-based coating, said substrates comprising at least one pharmacologically active ingredient in an amount to provide a concentration of active agent of at least about 50% in said microencapsulate, and said microencapsulate included in a one-component dosage unit in an amount of at least 50% by weight of said dosage unit such that said active ingredient exhibits modified release by dissolution throughout the therapeutic range prescribed for treating a patient in need of said active ingredient.